Increasing availability of high-quality medications, especially in outpatient settings should become a priority for the development of healthcare in the Russian Federation for the coming years. This would alleviate illness complications and decrease the use of more expensive types of medical assistance, as well as ease the financial burden on families. Today, only a limited number of individuals have access to medications in outpatient settings in Russia, with this expenditure (both budgetary and individual) representing 17% of the total spending on medications. In the EU countries this figure is three-fold larger with state co-financing at least 50%. Addressing this issue will help patients and provide a powerful, targeted stimulus for the development of the pharmaceutical industry and science in Russia. How important is it to increase the volume of free medicines provided in outpatient settings, and what share of the cost should be borne by individuals? Should the structure of the pharmaceutical consumption in Russia undergo changes? Which medicines are vital to ensure that the quality of care in Russia meets international standards? What legal barriers must be removed to increase the efficiency of state procurement of medicines from the perspective of manufacturers, distributors and consumers (state and medical organizations)? Can players in the pharmaceutical market propose breakthrough solutions for providing medications to the Russian population?